Download the MMV-supported projects slide ⁄ Download the Global Portfolio of Antimalarial Medicines slide
For more information about the global malaria portfolio, read the article: Malaria medicines: a glass half full?
Detailed information is available for translational, development and access projects (click on the boxes below).
Last updated July 2019
MMV support to projects may include financial, in-kind, and advisory activities.
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.
Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ.
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Paediatric formulation.
1 Coartem® Dispersible
2 Artesun®
3 Eurartesim®
4 Pyramax® tablets or granules
5 ASAQ Winthrop®
6 SPAQ-COTM
7 100mg Artesunate Rectocaps
8 ArtecapTM
9 Kozenis/Krintafel (Trademarks owned or licensed by GSK)
10 Larinate® 60mg
Target Product Profiles - represented by coloured bar(s) under the project box
____ 3-day cure, artemisinin-based combination therapies
____ Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1
____ Severe malaria treatment and pre-referral intervention
____ Intermittent /seasonal malaria chemoprevention
____ Products targeting prevention of relapse for P. vivax
____ Single-exposure chemoprotection (SEC) TPP-2
Asexual blood stages
Relapse prevention
Transmission reduction
Prophylaxis